Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 33,180 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: HIV Infections
Interventions: Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,570 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more

Conditions: Autistic Disorder
Interventions: B12, Placebo, folate, B complex, vitamin C, cod liver oil, Mineral complex, carnitine; Dietary Supplement
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 3 Years to 7 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Cardiovascular Disease
Interventions: Soy Protein Powder (25g/d), Placebo, Soy Protein Powder (50g/d); Dietary Supplement
Lead sponsor: Penn State University; Other
Eligibility: 35 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Herpes Simplex
Interventions: 40 µg gE-gI, 80 µg gE-gI, 160 µg gE-gI, 40 µg gE-gI/AS01B, 80 µg gE-gI/AS01B, 60 µg gE-gI/AS01B, 40 µg gE-gI/AS01E, 80 µg gE-gI/AS01E, 160 µg gE-gI/AS01E, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more

Conditions: Type 2 Diabetes Mellitus
Interventions: AR-C165395XX, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Smoking, Nicotine, Tobacco, Addiction, Substance Use Disorders, Insomnia, Sleep
Interventions: Daridorexant 50 mg, Placebo; Drug · Other
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Migraine
Interventions: 91-day Levonorgestrel Oral Contraceptive, Placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: La Mesa, California • San Diego, California • San Francisco, California + 18 more

Conditions: Non-melanoma Skin Cancer
Interventions: topical diclofenac daily, placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
Interventions: mifepristone, placebo; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 22 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 42
States / cities: Little Rock, Arkansas • Anaheim, California • Downey, California + 34 more

Conditions: Neural Response in Caudate, Weight Loss Trial, Impulsivity
Interventions: PhosphoLean, Placebo; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: LY3526318, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 35
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 28 more

Conditions: Prostate Adenocarcinoma
Interventions: Fesoterodine, Placebo oral tablet; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 30 Years to 90 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Osteoarthritis, Knee
Interventions: astaxanthin, Placebo; Dietary Supplement · Other
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Seasonal Allergic Rhinitis
Interventions: Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo; Drug · Other
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years and older
Enrollment: 1,535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bronchopulmonary Dysplasia
Interventions: Inhaled Nitric Oxide (iNO), Nitrogen (placebo); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 72 Hours
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 6
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 3 more

Conditions: Schizophrenia
Interventions: Folic Acid, B12, Placebo; Dietary Supplement · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 68 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Boston, Massachusetts • Grand Rapids, Michigan • Rochester, New York

Conditions: Chronic Hepatitis B
Interventions: Vesatolimod, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 5 more

Conditions: Acanthamoeba Keratitis
Interventions: Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo; Drug · Other
Lead sponsor: Jeremy Keenan, MD, MPH; Other
Eligibility: 8 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 18
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Chemotherapy-Induced Peripheral Neuropathy, Malignant Solid Neoplasm
Interventions: Cannabidiol, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: Albert Lea, Minnesota • Grand Rapids, Minnesota • Hibbing, Minnesota + 6 more

Conditions: Parkinson's Disease
Interventions: Rotigotine, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: Reseda, California • Ventura, California • St. Petersburg, Florida + 4 more

Conditions: Systemic Sclerosis
Interventions: GLPG1690; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Los Angeles, California • Boca Raton, Florida • Ann Arbor, Michigan + 2 more

Conditions: Alzheimer's Disease
Interventions: Placebo, Gantenerumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 30
States / cities: Sun City, Arizona • Tucson, Arizona • Costa Mesa, California + 27 more

Conditions: Previously Treated Non Small Cell Lung Cancer
Interventions: AZD1775, AZD1775 Placebo, Antimitotic Agent, pegfiligrastim; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 9 more

Conditions: Pain
Interventions: Baclofen 10mg, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

Treating Oxidative Stress and the Metabolic Pathology of Autism

Effect of Soy on HDL-C Function, Central Blood Pressure, and Arterial Stiffness

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

Topical Chemoprevention of Skin Cancer Biomarkers

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns

Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

Parasitic Ulcer Treatment Trial

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

A Study of Gantenerumab in Participants With Mild Alzheimer Disease

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Baclofen as a Perioperative Analgesic Adjuvant